Bladder cancer 25 percent less likely if have high vitamin D – meta-analysis Oct 2014

Impact of serum vitamin D level on risk of bladder cancer: a systemic review and meta-analysis.

Tumour Biol. 2014 Oct 31.
Liao Y1, Huang JL, Qiu MX, Ma ZW.
Department of Urology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, No. 32, Section 2, West 1st Ring Road, Chengdu, 610072, China.

Vitamin D has important biological functions including modulation of the immune system and anti-cancer effects. There was no conclusive finding of the impact of serum vitamin D level on bladder cancer risk. A systemic review and meta-analysis was performed to assess the impact of serum 25-hydroxyvitamin D level on bladder cancer risk. The pooled relative risk (RR) with 95 % confidence interval (95%CI) was used to assess the impact of serum 25-hydroxyvitamin D level on bladder cancer risk. A total of 89,610 participants and 2238 bladder cancer cases were finally included into the meta-analysis. There was no obvious heterogeneity among those included studies (I 2 = 0 %).
Meta-analysis total included studies which showed that a high serum 25-hydroxyvitamin D level could obviously decrease risk of bladder cancer (RR = 0.75, 95%CI 0.65-0.87, P < 0.001). In addition, the pooled RRs were not significantly changed by excluding any single study. The findings from the meta-analysis suggest an obvious protective effect of vitamin D against bladder cancer. Individuals with higher serum 25-hydroxyvitamin D levels suffer from less risk of subsequent bladder cancer.
Publisher wants $39 for the PDF

References
  1. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, et al.
    Summary of the 8th annual bladder cancer think tank: collaborating to move research forward. Urol Oncol. 2014.
  2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. CrossRef
  3. Keimling M, Behrens G, Schmid D, Jochem C, Leitzmann MF. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer. 2014;110:1862–70. CrossRef
  4. Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC.
    Ultraviolet b irradiance and incidence rates of bladder cancer in 174 countries. Am J Prev Med. 2010;38:296–302. CrossRef
  5. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49. CrossRef
  6. Albert PJ, Proal AD, Marshall TG. Vitamin D: the alternative hypothesis. Autoimmun Rev. 2009;8:639–44. CrossRef
  7. Dixon KM, Mason RS. Vitamin D. Int J Biochem Cell Biol. 2009;41:982–5. CrossRef
  8. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010;9:941–55. CrossRef
  9. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8:685–98. CrossRef
  10. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94:26–34. CrossRef
  11. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol. 2014;810:500–25.
  12. Ordonez Mena JM, Brenner H. Vitamin D and cancer: an overview on epidemiological studies. Adv Exp Med Biol. 2014;810:17–32.
  13. Lee JE, Li H, Chan AT, et al. Circulating levels of vitamin D and colon and rectal cancer: the physicians’ health study and a meta-analysis of prospective studies. Cancer Prev Res (Phila). 2011;4:735–43. CrossRef
  14. Ordonez-Mena JM, Schottker B, Haug U, et al. Serum 25-hydroxyvitamin D and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2013;22:905–16. CrossRef
  15. Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014;110:2772–84. CrossRef
  16. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451–9. CrossRef
  17. Amaral AF, Mendez-Pertuz M, Munoz A, et al. Plasma 25-hydroxyvitamin D(3) and bladder cancer risk according to tumor stage and FGFR3 status: a mechanism-based epidemiological study. J Natl Cancer Inst. 2012;104:1897–904. CrossRef
  18. Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem. 2013;59:771–80. CrossRef
  19. Mondul AM, Weinstein SJ, Horst RL, Purdue M, Albanes D. Serum vitamin D and risk of bladder cancer in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2012;21:1222–5. CrossRef
  20. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer. 2012;107:1589–94. CrossRef
  21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. CrossRef
  22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. CrossRef
  23. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
  24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. CrossRef
  25. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med. 2007;26:4544–62. CrossRef
  26. Mondul AM, Weinstein SJ, Mannisto S, et al. Serum vitamin D and risk of bladder cancer. Cancer Res. 2010;70:9218–23. CrossRef
  27. Pommergaard HC, Burcharth J, Rosenberg J, Raskov H. Oral chemoprevention with acetyl salicylic acid, vitamin D and calcium reduces the risk of tobacco carcinogen-induced bladder tumors in mice. Cancer Invest. 2013;31:490–3. CrossRef
  28. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol. 2011;51:311–36. CrossRef
  29. Chen P, Li M, Gu X, et al. Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case–control study and meta-analysis of the observational studies. PLoS One. 2013;8:e49312. CrossRef
  30. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:827–38. CrossRef
  31. Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol. 2014;2:307–20. CrossRef

See also VitaminDWiki

6 Meta-anayses of Bladder Cancer

This list is automatically updated

3419 visitors, last modified 23 May, 2024,
Printer Friendly Follow this page for updates